PMID- 24720836
OWN - NLM
STAT- MEDLINE
DCOM- 20150223
LR  - 20170203
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 17
IP  - 7
DP  - 2014 Jul
TI  - Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a 
      time and motion study in the United Kingdom.
PG  - 459-68
LID - 10.3111/13696998.2014.914033 [doi]
AB  - OBJECTIVE: Rituximab is part of standard therapy for many non-Hodgkin lymphoma 
      (NHL) patients, and is usually administered as an intravenous (IV) infusion. A 
      formulation for subcutaneous (SC) injection will be available from June 2014. A 
      time and motion study was conducted to investigate the staff time and costs 
      associated with administration of SC and IV rituximab. RESEARCH DESIGN AND 
      METHODS: The time and motion study was conducted in three UK centers alongside a 
      phase III trial of SC rituximab in patients with NHL (ClinicalTrials.gov 
      identifier NCT01461928). Active healthcare professional (HCP) time spent on the 
      preparation and administration of IV and SC rituximab was recorded and used to 
      calculate the associated costs. RESULTS: Total active HCP time associated with 
      administration of IV rituximab was 223.3 min (95% CI = 218.0-228.7), vs 48.5 min 
      (95% CI = 45.5-51.6) for SC rituximab, a saving of 174.8 min (95% 
      CI = 172.5-177.1) per session. Patient time in the treatment room was 263.8 min 
      (95% CI = 236.6-294.3) for IV rituximab and 70.0 min (95% CI = 57.1-87.2) for SC 
      rituximab, per session. The SC formulation reduced total mean staff costs by 
       pound115.17 (95% CI = 98.95-136.93) per session. Differing monitoring scenarios 
      during infusion consistently showed time and cost savings for SC rituximab. 
      LIMITATIONS: Study limitations include the non-interventional design and lack of 
      statistical power, and the investigational nature of SC rituximab. The data 
      collected did not account for patient and center characteristics and variability 
      on active HCP time. CONCLUSIONS: SC rituximab was associated with reduced active 
      HCP time and costs vs IV rituximab, as well as reduced patient time in the 
      treatment room. Switching from IV to SC rituximab could increase treatment room 
      capacity and patient throughput, as well as improving the patient experience.
FAU - Rule, Simon
AU  - Rule S
AD  - Plymouth University Medical School and Derriford Hospital , Plymouth , UK.
FAU - Collins, Graham P
AU  - Collins GP
FAU - Samanta, Kunal
AU  - Samanta K
LA  - eng
SI  - ClinicalTrials.gov/NCT01461928
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140507
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antineoplastic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Administration, Intravenous/*economics
MH  - Antibodies, Monoclonal, Murine-Derived/*administration & 
      dosage/*economics/therapeutic use
MH  - Antineoplastic Agents/administration & dosage/economics/therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Costs and Cost Analysis
MH  - Health Personnel/*economics
MH  - Humans
MH  - Injections, Subcutaneous/*economics
MH  - Lymphoma, Non-Hodgkin/*drug therapy/economics
MH  - Outpatient Clinics, Hospital/economics
MH  - Prospective Studies
MH  - Rituximab
MH  - State Medicine/economics
MH  - *Time and Motion Studies
MH  - United Kingdom
OTO - NOTNLM
OT  - Cost
OT  - Intravenous infusion
OT  - Rituximab
OT  - Subcutaneous
OT  - Time and motion
EDAT- 2014/04/12 06:00
MHDA- 2015/02/24 06:00
CRDT- 2014/04/12 06:00
PHST- 2014/04/12 06:00 [entrez]
PHST- 2014/04/12 06:00 [pubmed]
PHST- 2015/02/24 06:00 [medline]
AID - 10.3111/13696998.2014.914033 [doi]
PST - ppublish
SO  - J Med Econ. 2014 Jul;17(7):459-68. doi: 10.3111/13696998.2014.914033. Epub 2014 
      May 7.